Form 4: Neurocrine Biosciences Director Sells Shares

Neurocrine Biosciences Director Leslie V. Norwalk sold 3,810 shares of common stock for approximately $155.01 per share, totaling over $590,000, as part of a pre-arranged trading plan.

Summary

• Leslie V. Norwalk, a Director at Neurocrine Biosciences Inc. (NBIX), reported a transaction on May 12, 2026.
• The transaction involved the disposition of 3,810 shares of common stock.
• These shares were sold at a weighted average price of $155.01, with individual sales ranging from $155.00 to $155.0550.
• The total value of the shares sold is approximately $590,555.50.
• The sale was executed through a broker under a Rule 10b5-1 trading plan adopted on September 15, 2025.
• Following the transaction, Norwalk beneficially owns 2,429 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While a director is selling shares, the transaction was conducted under a pre-established Rule 10b5-1 plan, which is a standard and regulated method for insider stock sales.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, indicating a planned and orderly disposition rather than a reaction to immediate market conditions.
• The shares were sold at a price point consistent with the market range at the time, suggesting no significant deviation from prevailing valuations.

Negatives

• A director has reduced their direct holdings in the company, which could be perceived negatively by some investors.
• The disposition of a significant number of shares (3,810) may signal a lack of confidence or a need for personal liquidity by the reporting person.

Risks

• The Rule 10b5-1 trading plan is designed to provide an affirmative defense against allegations of insider trading, but the adoption date of September 15, 2025, is noted.
• The company policy restricts the reporting person from amending or modifying the 10b5-1 trading plan after its adoption.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports a past transaction.

Management Comments

• The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025.
• Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
• Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.00 to $155.0550.
• The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Industry Context

StockSavvy.ai notes that insider selling, particularly under a Rule 10b5-1 plan, is a common occurrence for executives and directors to diversify holdings or manage personal finances. While it can sometimes be interpreted negatively, the use of a pre-planned trading strategy mitigates concerns about opportunistic insider trading.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the director's sale with caution, although the Rule 10b5-1 plan mitigates concerns about insider trading. The sale does reduce the director's direct equity stake.

Next Steps

• The reporting person will continue to hold 2,429 shares of common stock directly.
• Information regarding the number of shares sold at each price within the range will be provided to the issuer, security holders, or SEC staff upon request.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, Form 4, Insider Trading, Stock Sale, Director Transaction, Rule 10b5-1, Beneficial Ownership, Common Stock